These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
6. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Nishikido T Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882 [TBL] [Abstract][Full Text] [Related]
7. Inclisiran: A Review in Hypercholesterolemia. Frampton JE Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872 [TBL] [Abstract][Full Text] [Related]
9. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Sinning D; Landmesser U Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390 [TBL] [Abstract][Full Text] [Related]
10. Inclisiran: How Widely and When Should We Use It? Pirillo A; Catapano AL Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035 [TBL] [Abstract][Full Text] [Related]
11. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Arnold N; Koenig W Curr Cardiol Rep; 2022 Nov; 24(11):1657-1667. PubMed ID: 36087240 [TBL] [Abstract][Full Text] [Related]
13. Inclisiran-New hope in the management of lipid disorders? Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073 [TBL] [Abstract][Full Text] [Related]
14. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. Gaine SP; Quispe R; Patel J; Michos ED Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094 [TBL] [Abstract][Full Text] [Related]
15. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352 [TBL] [Abstract][Full Text] [Related]
16. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]. Scheen AJ; Wallemacq C; Lancellotti P Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
18. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231 [TBL] [Abstract][Full Text] [Related]
19. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005 [TBL] [Abstract][Full Text] [Related]
20. Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia. Hughes-Hubley F; Iskander M; Cheng-Lai A; Frishman WH; Nawarskas J Cardiol Rev; 2022 Jul-Aug 01; 30(4):214-219. PubMed ID: 35666780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]